Surgical Science Q2 2025 - Expect continued volatility

Redeye updates its estimates following Surgical Science’s Q2 2025 report, which aligned with the company’s profit warning and broadly underperformed our original projections. While we believe coming quarters should present better figures, we lower our estimates and valuation. Despite worse-than-expected short-term development, we judge Surgical Science’s long-term potential remains essentially unchanged.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/